ArticlePharmaceuticals (Basel, Switzerland)2026
Off-Label Ustekinumab and Vedolizumab in Pediatric Anti-TNFα Refractory IBD: Therapeutic Drug Monitoring Insights from a Case Series.
Stefania Cheli et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.